Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Scinopharm Taiwan's Enterprise Value is NT$14,100 Mil.
Scinopharm Taiwan's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was NT$157 Mil. Therefore, Scinopharm Taiwan's EV-to-EBIT ratio for today is 89.67.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Scinopharm Taiwan's Enterprise Value is NT$14,100 Mil.
Scinopharm Taiwan's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was NT$674 Mil. Therefore, Scinopharm Taiwan's EV-to-EBITDA ratio for today is 20.92.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Scinopharm Taiwan's Enterprise Value is NT$14,100 Mil.
Scinopharm Taiwan's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was NT$3,163 Mil. Therefore, Scinopharm Taiwan's EV-to-Revenue ratio for today is 4.46.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Scinopharm Taiwan (TPE:1789) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Scinopharm Taiwan's current Enterprise Value is NT$14,100 Mil.
Scinopharm Taiwan's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$157 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Scinopharm Taiwan's current Enterprise Value is NT$14,100 Mil.
Scinopharm Taiwan's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$674 Mil.
Scinopharm Taiwan's current Enterprise Value is NT$14,100 Mil.
Scinopharm Taiwan's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$3,163 Mil.
Scinopharm Taiwan's current Enterprise Value is NT$14,100 Mil.
Scinopharm Taiwan's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$596 Mil.
Scinopharm Taiwan's current Enterprise Value is NT$14,100 Mil.
Scinopharm Taiwan's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$300 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scinopharm Taiwan Enterprise Value Related Terms
Scinopharm Taiwan Enterprise Value Historical Data
* Premium members only.
The historical data trend for Scinopharm Taiwan's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1789 vs ZTS, UTHR: Enterprise Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Scinopharm Taiwan's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scinopharm Taiwan Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Scinopharm Taiwan's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Scinopharm Taiwan's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Scinopharm Taiwan's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of NT$14,100 Mil mean?
Scinopharm Taiwan (TPE:1789) has a Enterprise Value of NT$14,100 Mil as of Jul. 02, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Scinopharm Taiwan and its competitors.
Is Scinopharm Taiwan's Enterprise Value too high?
Scinopharm Taiwan's current Enterprise Value is NT$14,100 Mil. Overall, Scinopharm Taiwan has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scinopharm Taiwan's Enterprise Value compare to ZTS and UTHR?
Scinopharm Taiwan's Enterprise Value of NT$14,100 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Scinopharm Taiwan and its competitors. Scinopharm Taiwan's current Enterprise Value is NT$14,100 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinopharm Taiwan stock overvalued right now?
Based on GuruFocus' analysis, Scinopharm Taiwan (TPE:1789) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$27.12, compared to a current price of NT$20.80 — trading 23.3% below its estimated fair value. The current Enterprise Value is NT$14,100 Mil. Scinopharm Taiwan's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Scinopharm Taiwan (TPE:1789), the current Enterprise Value is NT$14,100 Mil as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scinopharm Taiwan (TPE:1789) Overvalued in 2026?
Based on GuruFocus' analysis, Scinopharm Taiwan stock appears to be undervalued.
The current stock price of NT$20.80 is trading 23.3% below its estimated GF Value™ of NT$27.12.
GuruFocus considers Scinopharm Taiwan to be Modestly Undervalued.
Key valuation signals for TPE:1789:
Enterprise Value: NT$14,100 Mil
GF Value™: NT$27.12 vs. price of NT$20.80 (23.3% below fair value)
No single metric tells the full story. See the TPE:1789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scinopharm Taiwan Ltd is mainly engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade, and the research, development, production, manufacture, and sales of Active Pharmaceutical Ingredients (API), albumin medicines, oligonucleotide medicines, peptide medicines, injections, and new small molecule drugs. The Company also provides related consulting and technical services and international trade for the above products. In addition, the Company sells chemical material reprocessed from material recycled from the Company's manufacturing process.
76GF Score
Get the complete analysis for TPE:1789
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1789 has been successfully added to your 
